

# Research and Diagnosis of Inherited Metabolic Diseases Group



Publications: 19

Impact Factor: 92.058

QI: 12

## Research Activity

### DOCTORAL THESES

Medrano Rodríguez C. Bases Moleculares de los defectos congénitos de glicosilación [dissertation]. Madrid: UAM; 2017(01/03/2017).

Directors: Pérez González B, Pérez Cerdá C.

### BOOKS AND BOOK CHAPTERS

**Cornejo V , Raimann B, Pérez González B, Ruiz Desviat L, Arias C.** Bases moleculares y cromosómicas de las enfermedades genéticas. Hiperfenilalaninemias. In: Colombo M, Cornejo V, Raimann E, (Eds). Errores Innatos en el Metabolismo del Niño. Chile: Editorial universitaria, 2017. Capítulo 3

**Pérez González B, Ruiz Desviat L, Martínez M.** Bases moleculares y cromosómicas de las enfermedades genéticas. Deficiencia de Pterinas. In: Colombo M, Cornejo V, Raimann E, (Eds). Errores Innatos en el Metabolismo del Niño. Chile: Editorial universitaria, 2017. Capítulo 3

**Pérez González B, Ruiz Desviat L.** Bases moleculares y cromosómicas de las enfermedades genéticas. Genética molecular de enfermedades metabólicas hereditarias y herramientas diagnósticas más usadas en genética molecular. In: Colombo M, Cornejo V, Raimann E, (Eds). Errores Innatos en el Metabolismo del Niño. Chile: Editorial universitaria, 2017. Capítulo 1


### PUBLICATIONS

- Alonso-Barroso E, Brasil S, Briso-Montiano A, Navarrete R, Pérez-Cerdá C, Ugarte M, Pérez B, Desviat LR, Richard E. Generation and characterization of a human iPSC line from a patient with propionic acidemia due to defects in the PCCA gene. *Stem Cell Res.* 2017; 23: 173-7. Editorial Material. IF: 1.829; Q3

- Bellusci M, Quijada-Fraile P, Barrio-Carreras D, Martín-Hernández E, García-Silva M, Merinero B, Pérez B, Hernández-Lain A. Carnitine palmitoyltransferase 1A deficiency: abnormal muscle biopsy findings in a child presenting with Reye's syndrome. *J Inherit Metab Dis.* 2017; 40(5): 751-2. Editorial Material. IF: 4.092; Q1
- Bravo-Alonso I, Navarrete R, Arribas-Carreira L, Perona A, Abia D, Couce ML, García-Cazorla A, Morais A, Domingo R, Ramos MA, Swanson MA, Van Hove JJK, Ugarte M, Pérez B, Pérez-Cerdá C, Rodríguez-Pombo P. Nonketotic hyperglycinemia: Functional assessment of missense variants in GLDC to understand phenotypes of the disease. *Hum Mutat.* 2017; 38(6): 678-91. Article. IF: 5.359; Q1
- Cabezas OR, Flanagan SE, Stanescu H, García-Martínez E, Caswell R, Lango-Allen H, Antán-Gamero M, Argente J, Busse AM, Brandli A, Cheshire C, Crowne E, Dumitriu S, Drynda R, Hamilton-Shield JP, Hayes W, Hofherr A, Iancu D, Issler N, Jefferies C, Jones P, Johnson M, Kesselheim A, Klootwijk E, Koettgen M, Lewis W, Martos JM, Mozere M, Norman J, Patel V, Parrish A, Pérez-Cerdá C, Pozo J, Rahman SA, Sebire N, Tekman M, Turnpenny PD, van't Hoff W, Viering DHM, Weedon MN, Wilson P, Guay-Woodford L, Kleta R, Hussain K, Ellard S, Bockenhauer D. Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2. *J Am Soc Nephrol.* 2017; 28(8): 2529-39. Article. IF: 8.655; DI

- Casado M, Ferrer-López I, Ruiz-Sala P, Pérez-Cerdá C, Artuch R. Urine oligosaccharide tests for the diagnosis of oligosaccharidoses. *Rev Anal Chem.* 2017; 36(3): 20160019. Article. IF: 2.111; Q2
- Couce ML, Aldamiz-Echevarría L, Bueno MA, Barros P, Belanger-Quintana A, Blasco J, García-Silva MT, Márquez-Armenteros AM, Vitoria I, Vives I, Navarrete R, Fernández-Marmiesse A, Pérez B, Pérez-Cerdá C. Genotype and phenotype characterization in a Spanish cohort with isovaleric acidemia. *J Hum Genet.* 2017; 62(3): 355-60. Article. IF: 2.942; Q2
- Coughlin CR, Swanson MA, Kronquist K, Acquaviva C, Hutchin T, Rodríguez-Pomba P, Väisanen ML, Spector E, Creadon-Swindell

# Cancer and Human Molecular Genetics Area



- G, Bras-Goldberg AM, Rahikka E, Moilanen JS, Mahieu V, Matthijs G, Bravo-Alonso I, Pérez-Cerdá C, Ugarte M, Vianey-Saban C, Scharer GH, Van Hove JLK. The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT. *Genet Med.* 2017; 19(1): 104-11. Article. IF: 9.937; Q1
- de Diego V, Martínez-Monseny AF, Muchart J, Cuadras D, Montero R, Artuch R, Pérez-Cerdá C, Pérez B, Pérez-Duenas B, Poretti A, Serrano M. Longitudinal volumetric and 2D assessment of cerebellar atrophy in a large cohort of children with phosphomannomutase deficiency (PMM2-CDG). *J Inherit Metab Dis.* 2017; 40(5): 709-13. Article. IF: 4.092; Q1
  - Godfrey C, Desviat LR, Smedsrød B, Pietri-Rouxel F, Denti MA, Diszterer P, Lorain S, Nogales-Gadea G, Sardone V, Anwar R, El Andaloussi S, Lehto T, Khoo B, Brolin C, van Roon-Mom WMC, Goyenvaille A, Aartsma-Rus A, Arechavala-Gómez V. Delivery is key: lessons learnt from developing splice-switching antisense therapies. *EMBO Mol Med.* 2017; 9(5): 545-57. Review. IF: 10.293; Q1
  - Ortigoza-Escobar JD, Alfadhel M, Molero-Luis M, Darin N, Spiegel R, de Coo IF, Gerards M, Taylor RW, Artuch R, Nashabat M, Rodríguez-Pombo P, Tabarki B, Pérez-Dueñas B. Thiamine deficiency in childhood with attention to genetic causes: Survival and outcome predictors. *Ann Neurol.* 2017; 82(3): 317-30. Article. IF: 10.244; Q1
  - Peña-Quintana L, Scherer G, Curbelo-Estevez ML, Jiménez-Acosta F, Hartmann B, La Roche F, Meavilla-Olivas S, Pérez-Cerdá C, García-Segarra N, Giguere Y, Hupke P, Mitchell GA, Monch E, Trump D, Vianey-Saban C, Trimble ER, Vitoria-Miñana I, Reyes-Suárez D, Ramírez-Lorenzo T, Tugores A. Tyrosinemia type II: Mutation update, 11 novel mutations and description of 5 independent subjects with a novel founder mutation. *Clin Genet.* 2017; 92(3): 306-17. Article. IF: 3.512; Q2
  - Pérez-Cerdá C, Girós ML, Serrano M, Ecay MJ, Gort L, Dueñas BP, Medrano C, García-Alix A, Artuch R, Briones P, Pérez B. A population-based study on congenital disorders of protein N- and combined with o-glycosylation experience in clinical and genetic diagnosis. *J Pediatr-US.* 2017; 183: 170-7. Article. IF: 3.667; Q1
  - Rice GI, Kitabayashi N, Barth M, Briggs TA, Burton ACE, Carpanelli ML, Cerisola AM, Colson C, Dale RC, Danti FR, Darin N, de Azua B, de Giorgis V, de Goede CGL, Desguerre I, de Laet C, Eslahi A, Fahey MC, Fallon P, Fay A, Fazzi E, Gorman MP, Gowrinathan NR, Hully M, Kurian MA, Leboucq N, Lin JPSM, Lines MA, Mar SS, Maroofian R, Martí-Sánchez L, McCullagh G, Mojarrad M, Narayanan V, Orcesi S, Ortigoza-Escobar JD, Pérez-Dueñas B, Petit F, Ramsey KM, Rasmussen M, Rivier F, Rodríguez-Pombo P, Roubertie A, Stodberg TI, Toosi MB, Toutain A, Uettwiller F, Ulrick N, Vanderver A, Waldman A, Livingston JH, Crow YJ. Genetic, phenotypic, and interferon biomarker status in ADAR1-related neurological disease. *Neuropediatrics.* 2017; 48(3): 166-84. Article. IF: 1.605; Q3
  - Rivera-Barahona A, Alonso-Barroso E, Pérez B, Murphy MP, Richard E, Desviat LR. Treatment with antioxidants ameliorates oxidative damage in a mouse model of propionic acidemia. *Mol Genet Metab.* 2017; 122(43132): 43-50. Article. IF: 3.774; Q2
  - Rivera-Barahona A, Fulgencio-Covián A, Pérez-Cerdá C, Ramos R, Barry MA, Ugarte M, Pérez B, Richard E, Desviat LR. Dysregulated miRNAs and their pathogenic implications for the neurometabolic disease propionic acidemia. *SCI Rep-Uk.* 2017; 7: 5727. Article. IF: 4.122; Q1
  - Rivera-Barahona A, Pérez B, Richard E, Desviat LR. Role of miRNAs in human disease and inborn errors of metabolism. *J Inherit Metab Dis.* 2017; 40(4): 471-80. Article. IF: 4.092; Q1
  - Serrano NL, de Diego V, Cuadras D, Monseny AFM, Velázquez-Fragua R, López L, Felipe A, Gutiérrez-Solana LG, Macaya A, Pérez-Dueñas B, Serrano M. A quantitative assessment of the evolution of cerebellar syndrome in children with phosphomannomutase-deficiency (PMM2-CDG). *Orphanet J Rare Dis.* 2017; 12: 155. Article. IF: 3.607; Q2
  - Yuste-Checa P, Brasil S, Gámez A, Underhaug J, Desviat LR, Ugarte M, Pérez-Cerdá C, Martínez A, Pérez B. Pharmacological chaperoning: A potential treatment for PMM2-CDG. *Hum Mutat.* 2017; 38(2): 160-8. Article. IF: 5.359; Q1
  - Yuste-Checa P, Vega AI, Martín-Higueras C, Medrano C, Gámez A,

Desviat LR, Ugarte M, Pérez-Cerdá C, Pérez B. DPAGTI-CDG: Functional analysis of disease causing pathogenic mutations and role of endoplasmic reticulum stress. *Plos One.* 2017; 12(6): e0179456. Article. IF: 2.766; Q1

## PUBLIC PROJECTS

**Pérez González MB.** Enfermedades neurometabólicas hereditarias: avances en el diagnóstico, la patofisiología y desarrollo de terapias dirigidas a estabilizar proteínas. (PI16/00573). ISCIII. 2017-2019.

Management centre: UAM

**Ruiz Desviat MI.** Propionic acidemia: from models and mechanisms to biomarkers and therapies. (SAF2016-76004-R). MINECO. 2017-2019.

Management centre: UAM

## PRIVATE PROJECTS

**Pérez González MB.** Bases moleculares de las enfermedades neurometabólicas y desarrollo de terapias específicas de mutación. Fundación Isabel Gemio. 2016-2020.

Management centre: Fundación Severo Ochoa

**Pérez González MB.** Bases moleculares del síndrome de deficiencia Glut1 (Glut1ds) e investigación en terapias. CIBERER. 2017-Ongoing.

Management centre: CIBERER

**Ruiz Desviat L.** Análisis genómicos y transcriptómicos para identificar defectos de Splicing y evaluación in vivo de la terapia antisentido. Fundación Ramón Areces. 2015-2018.

Management centre: Fundación Severo Ochoa

## INTERNATIONAL PROJECTS

**Pérez González MB.** European research network directed towards improving diagnosis and treatment of inborn error of glycosylation (E-rare-3 JTC2015). European Union. 2016-2018.

Management centre: UAM

**Pérez González MB.** Strengthening the research potential of image through reinforcement of biomedical science of rare diseases in Serbia – en route for innovation (Serbordisinn) (FP7-REGPOT). European Union. 2013-2016.

Management centre: UAM

**Ruiz Desviat MI.** Networking towards clinical application of antisense-mediated exon skipping. European cooperation in science and technology (COST BM1207). European Union. 2013-2017.

Management centre: UAM

## PATENTS AND TRADEMARKS

**Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R,** inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11.

**Pérez González B, Gámez Abascal A, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J,** inventors; UAM, Universidad de Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EP16382373.5; 2016.